Skip to main content

Table 2 Peri-operative data

From: Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up

 Ulinastatin group
(n = 142)
Tranexamic acid group (n = 143)Placebo group
(n = 141)
P
Surgical procedures0.733
 On-pump coronary artery bypass grafting, n (%)16 (11.27%)13 (9.09%)21 (14.89%) 
 Mitral valvuloplasty/replacement, n (%)66 (46.48%)65 (45.45%)60 (42.55%) 
 Aortic valve replacement, n (%)23 (16.20%)21 (14.69%)19 (13.48%) 
 Mitral and aortic valve replacement, n (%)17 (11.97%)15 (10.49%)15 (10.64%) 
 Coronary bypass and valvular surgery, n (%)10 (7.04%)7 (4.90%)7 (4.96%) 
 Repair of atrial septal defect, n (%)1 (0.70%)4 (2.80%)6 (4.26%) 
 Repair of ventricular septal defect, n (%)4 (2.82%)6 (4.20%)5 (3.55%) 
 Other5 (3.52%)12 (8.39%)8 (5.67%) 
Operative data
 Total dose of heparin (IU/kg)28,331.69 ± 6695.9628,729.51 ± 6612.3928,653.19 ± 6738.070.924
 Total dose of protamine (mg)393.28 ± 111.35408.17 ± 117.55407.87 ± 111.60.415
 Heparin neutralization ratio1.41 ± 0.341.45 ± 0.381.46 ± 0.390.510
 Aortic cross-clamp time (min)75.23 ± 34.868.77 ± 34.5672.32 ± 38.090.186
 CPB time (min)102.87 ± 42.7495.60 ± 42.0798.69 ± 47.760.205
 Chest closure time (min)66.71 ± 30.4464.04 ± 24.867.04 ± 30.930.888
 Operation time (min)216.8 ± 64.03206.46 ± 62.25205.28 ± 65.360.156
 Inotropic support, n (%)141 (99.3%)140 (97.9%)138 (97.87%)0.559
 Operative mortality000
Postoperative time course
 Mechanical ventilation (hrs)15.0 ± 7.6614.92 ± 10.5816.95 ± 20.850.609
 ICU stay (hrs)38.94 ± 26.9138.06 ± 29.9442.23 ± 35.30.741
 Chest tube removal (hrs)50.39 ± 25.6849.92 ± 18.2948.01 ± 23.540.649
 Hospital length of stay (days)8.24 ± 3.198.05 ± 2.468.51 ± 2.790.338